CNS Program

About Creyon Bio

Creyon Bio is a private, pre-clinical biotech company pioneering a novel approach to RNA drug delivery using aptamers and artificial intelligence. Its core technology platform aims to overcome key limitations of traditional antibody-based delivery and lipid nanoparticles by enabling precise, cell-specific targeting of therapeutic payloads like siRNA and ASOs. The company has established preclinical proof-of-concept in three therapeutic areas—immunology, CNS, and neuromuscular diseases—and is advancing a wholly-owned pipeline. Creyon represents a convergence of next-generation delivery science and computational drug design, positioning it to develop potentially safer and more effective RNA therapies.

About nChroma Bio

nChroma Bio is a private, preclinical-stage biotech founded in 2020 and headquartered in Boston, MA, USA. The company is pioneering a disease-first approach to genetic medicine, integrating epigenetic and gene-editing cargoes with a modular delivery platform (LNPs for liver, eVLPs for extrahepatic tissues) to create durable, targeted therapies. Its pipeline includes a Phase 1/2 candidate for chronic HBV and earlier research programs in cardiometabolic and CNS diseases, positioning it to address significant unmet needs in both hepatic and non-liver indications.

About Korro Bio

Korro Bio is a clinical-stage biotechnology company developing RNA editing therapies via its proprietary OPERA® platform, which co-opts the endogenous ADAR enzyme to make precise adenosine-to-inosine edits. The company has built a diversified pipeline of wholly-owned programs, with its lead candidate, KRRO-121, advancing towards the clinic for hyperammonemia. Korro's strategy leverages validated delivery technologies like GalNAc and LNPs to target high-need indications in the liver and CNS, supported by recent capital raises including an $85 million private placement in March 2026.

Therapeutic Areas